Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FT-IR Spectrometer

By Drug Discovery Trends Editor | March 10, 2009

ABB unveiled its MB3000-PH FT-IR spectrometer for the pharmaceutical and life sciences industries at PITTCON 2009. The MB3000-PH is designed for QA/QC, formulation, research, and development laboratories. It features Horizon MB FTIR software and combines all the attributes of a research grade instrument, while maintaining a minimal cost of ownership, according to ABB.  The MB3000’s new design and metrology allow the user to operate the instrument without any scheduled maintenance for a period of 10 years, according to the company.

Whether operating in QA/QC, analytical development, R&D, or formulation laboratory, users can enjoy the simplicity and ease of use of the MB3000-PH. Thanks to its universal sampling compartment, the analyzer is highly versatile and accommodates a wide range of accessories. The Horizon MB FTIR software suite offers an intuitive and user-friendly interface allowing immediate adaptation for new users, according to the company.

ABB engineers have paid great attention to ensure that the MB3000-PH delivers the high-quality type of spectra that have contributed to the world-class reputation of ABB analyzers over the years, as illustrated by the outstanding signal-to-noise specifications of the MB3000-PH: typically 50000:1 RMS noise (60s, 4 cm-1), according to ABB.

Visit ABB at Pittcon 2009 at Booth #2213.

www.abb.com


Filed Under: Drug Discovery

 

Related Articles Read More >

Red blood cells macro over red eritrosit background. Concept of blood cells count, medicine and healthcare. 3d rendering mock up
Platelet-inspired nanoparticle delivers drugs directly where they are needed
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
China’s biopharma sector enters ‘innovation 2.0’ era
The FDA’s AI ambitions depend on better data practices
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE